What is AliveCor?
AliveCor, Inc. is a pioneering medical software company founded in 2010 and headquartered in Mountain View, California. It specializes in enabling users to record personal EKGs anytime and anywhere through its flagship KardiaMobile devices. The KardiaMobile 6L, coupled with KardiaCare, offers the capability to capture six-lead EKGs and detect six common arrhythmias. The company also provides the KardiaMobile Card, a credit card-sized device for on-the-go medical-grade EKG recordings. AliveCor's innovative approach positions it at the forefront of remote patient monitoring and personal cardiology.
How much funding has AliveCor raised?
AliveCor has raised a total of $154.6M across 7 funding rounds:
Series A
$3.3M
Series B
$10.5M
Series C
$20M
Series D
$30M
Debt
$20M
Other Financing Round
$5.8M
Series E
$65M
Series A (2011): $3.3M with participation from Burrill & Co.,, Qualcomm Ventures, and Oklahoma Life Science Fund
Series B (2012): $10.5M led by Burrill & Co.,, Qualcomm Ventures, Oklahoma Life Science Fund, and Khosla Ventures
Series C (2016): $20M supported by WP Global Partners
Series D (2017): $30M featuring Mayo Clinic and Omron Healthcare
Debt (2019): $20M backed by Oxford Finance
Other Financing Round (2019): $5.8M, investors not publicly disclosed
Series E (2020): $65M led by WP Global Partners, Qualcomm Ventures, BOLD Capital Partners, Khosla Ventures, and OMRON Corporation
Key Investors in AliveCor
Qualcomm Ventures
Qualcomm Ventures is the venture capital arm of Qualcomm Incorporated, a global leader in wireless technology. They invest in companies that drive innovation in mobile, connectivity, and related technologies, often focusing on early-stage and growth-stage companies.
Khosla Ventures
Khosla Ventures is a venture capital firm that provides funding and strategic advice to entrepreneurs working on breakthrough technologies across various sectors, including health, AI, and sustainable energy.
Mayo Clinic
Mayo Clinic is a world-renowned nonprofit academic medical center focused on integrated clinical practice, education, and research. Their investment in AliveCor highlights a commitment to advancing medical technology and patient care through innovation.
What's next for AliveCor?
With its recent major strategic investment and a history of significant enterprise-level funding, AliveCor is well-positioned for continued expansion and innovation. The company's focus on developing and deploying advanced personal EKG technology suggests a trajectory towards broader market penetration and the enhancement of its service offerings. Future developments are likely to involve further integration of AI for diagnostic support, expansion into new geographic markets, and strategic partnerships within the healthcare ecosystem to solidify its role in proactive cardiac care.
See full AliveCor company page
